Literature DB >> 12923824

Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain.

Murad Atmaca1, Murat Kuloglu, Ertan Tezcan, Bilal Ustundag.   

Abstract

It has been reported that nizatidine may reduce the weight gain in schizophrenic patients receiving olanzapine treatment. Previous studies have demonstrated a relation between olanzapine-induced weight gain and serum leptin levels. Therefore, in the present study, it was planned to investigate the efficacy of nizatidine on the treatment of olanzapine-induced weight gain, and if available, whether leptin levels were associated with reductions in weight gain. Of the patients with schizophrenia on olanzapine treatment, 59 who gave informed consent entered a 3 month open-label screening period. Of them, 35 patients (59%) showed weight gain in excess of 2.5 kg. These patients were randomly divided into two groups; olanzapine plus nizatidine (group I) and olanzapine plus placebo (group II) for an 8-week double-blind phase. The patients were evaluated at the baseline and at week 8 with respect to the positive and negative syndrome scale, body mass index, weight and serum leptin levels. In the open-label period, olanzapine led to a considerable marked increase in weight and in serum leptin levels. There was no statistically significant difference between the groups with respect to weight at the beginning of the 8-week double-blind treatment period. Throughout the 8 week double-blind period, in group I, the weight decreased by 4.5 +/- 2.2 kg ( p<0.05). In contrast, weight increased in group II by a mean of 2.3 +/- 0.9 kg ( p>0.05). The leptin levels decreased by 4.4 +/- 2.3 ng/ml in group I ( p<0.01), and increased by 1.8 +/- 0.6 ng/ml in group II ( p>0.05). These changes were accompanied by changes in the leptin levels in both groups I and II. It is concluded that leptin seems to be strongly associated with olanzapine-induced weight gain and that nizatidine treatment may reduce the weight gain and the correlated leptin levels in patients with schizophrenia on olanzapine treatment. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12923824     DOI: 10.1002/hup.514

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  18 in total

Review 1.  Management of antipsychotic-related weight gain.

Authors:  Lawrence Maayan; Christoph U Correll
Journal:  Expert Rev Neurother       Date:  2010-07       Impact factor: 4.618

Review 2.  Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis.

Authors:  Lawrence Maayan; Julia Vakhrusheva; Christoph U Correll
Journal:  Neuropsychopharmacology       Date:  2010-03-24       Impact factor: 7.853

Review 3.  [Antipsychotic drug-induced changes in metabolism].

Authors:  Julia Engl; Alexander Tschoner; Markus Laimer; Maria Rettenbacher; W Wolfgang Fleischhacker; Josef R Patsch; Christoph Ebenbichler
Journal:  Wien Klin Wochenschr       Date:  2006-05       Impact factor: 1.704

Review 4.  Interventions to reduce weight gain in schizophrenia.

Authors:  G Faulkner; T Cohn; G Remington
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

5.  Interventions for the metabolic syndrome in schizophrenia: a review.

Authors:  Evangelos Papanastasiou
Journal:  Ther Adv Endocrinol Metab       Date:  2012-10       Impact factor: 3.565

Review 6.  Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis.

Authors:  Yuya Mizuno; Takefumi Suzuki; Atsuo Nakagawa; Kazunari Yoshida; Masaru Mimura; Walter Wolfgang Fleischhacker; Hiroyuki Uchida
Journal:  Schizophr Bull       Date:  2014-03-17       Impact factor: 9.306

7.  Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers.

Authors:  Jess G Fiedorowicz; Del D Miller; Jeffrey R Bishop; Chadi A Calarge; Vicki L Ellingrod; William G Haynes
Journal:  Curr Psychiatry Rev       Date:  2012-02-01

Review 8.  Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin.

Authors:  Hua Jin; Jonathan M Meyer; Sunder Mudaliar; Dilip V Jeste
Journal:  Schizophr Res       Date:  2008-01-18       Impact factor: 4.939

Review 9.  Pharmacological management of atypical antipsychotic-induced weight gain.

Authors:  Trino Baptista; Yamily ElFakih; Euderruh Uzcátegui; Ignacio Sandia; Eduardo Tálamo; Enma Araujo de Baptista; Serge Beaulieu
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

10.  Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis.

Authors:  Virginia L Stauffer; Ilya Lipkovich; Vicki Poole Hoffmann; Alexandra N Heinloth; H Scott McGregor; Bruce J Kinon
Journal:  BMC Psychiatry       Date:  2009-03-28       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.